ecNumber*3.4.21.109#molecularWeight*110#molecularWeightMaximum*#commentary*Western blot analysis using seminal fluid, seminal fluid contains only activated matriptase in complex with antithrombin III, supposed 70 kDa active matriptase and a 40 kDa antithrombin III-fragment#organism*Homo sapiens#literature*707054#!ecNumber*3.4.21.109#molecularWeight*25000#molecularWeightMaximum*#commentary*serine protease domain, identified by SDS-PAGE, Western blot analysis and LC-MS,MS, without serpin complex#organism*Homo sapiens#literature*695463#!ecNumber*3.4.21.109#molecularWeight*26000#molecularWeightMaximum*#commentary*determined by SDS-PAGE#organism*Homo sapiens#literature*695506#!ecNumber*3.4.21.109#molecularWeight*28000#molecularWeightMaximum*#commentary*catalytic domain, Asp603 - Val855, after treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis; extracellular domains, Tyr81 - Val855, after treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis#organism*Rattus norvegicus#literature*696852#!ecNumber*3.4.21.109#molecularWeight*28000#molecularWeightMaximum*#commentary*Western blot analysis using conditioned medium, catalytic domain of proteolytically active two-chain matriptase C-terminal fragment#organism*Rattus norvegicus#literature*707795#!ecNumber*3.4.21.109#molecularWeight*28000#molecularWeightMaximum*#commentary*SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, activated C-terminal part consiting of the catalytic domain; SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, activated form of matriptase#organism*Rattus norvegicus#literature*708273#!ecNumber*3.4.21.109#molecularWeight*28000#molecularWeightMaximum*#commentary*SDS-PAGE and Western blot analysis, reducing conditions, activated matriptase, disulfide-linked two-chain C-terminal fragment#organism*Rattus norvegicus#literature*708947#!ecNumber*3.4.21.109#molecularWeight*29000#molecularWeightMaximum*#commentary*refolded zymogen#organism*Homo sapiens#literature*673645#!ecNumber*3.4.21.109#molecularWeight*29000#molecularWeightMaximum*#commentary*amino acids 596-855, theoretical molecular mass#organism*Homo sapiens#literature*697904#!ecNumber*3.4.21.109#molecularWeight*30000#molecularWeightMaximum*#commentary*catalytic domain, Asp603 - Val855, before treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis#organism*Rattus norvegicus#literature*696852#!ecNumber*3.4.21.109#molecularWeight*30000#molecularWeightMaximum*#commentary*serine protease domain, determined by SDS-PAGE and Western blot analysis#organism*Homo sapiens#literature*697182#!ecNumber*3.4.21.109#molecularWeight*30000#molecularWeightMaximum*#commentary*SDS-PAGE reducing conditions and Western blot using anti-rat matriptase catalytic domain anibody, designated pseudozymogen His6t-S-CD consisting of a spacer and the catalytical domain with an N-terminal His6-tag and a cleavage site for activation by enterokinase, after cleavage with enterokinase#organism*Rattus norvegicus#literature*708348#!ecNumber*3.4.21.109#molecularWeight*30000#molecularWeightMaximum*#commentary*x * 30000, catalytic domain of matriptase-2, SDS-PAGE#organism*Homo sapiens#literature*717966#!ecNumber*3.4.21.109#molecularWeight*30000#molecularWeightMaximum*#commentary*x * 70000, matriptase zymogen, SDS-PAGE, x * 30000, matriptase serine protease domain, SDS-PAGE#organism*Homo sapiens#literature*732088#!ecNumber*3.4.21.109#molecularWeight*32000#molecularWeightMaximum*#commentary*SDS-PAGE reducing and non-reducing conditions and Western blot using anti-rat matriptase catalytic domain anibody, designated pseudozymogen His6t-S-CD consisting of a spacer and the catalytical domain with an N-terminal His6-tag and a cleavage site for activation by enterokinase, before cleavage with enterokinase#organism*Rattus norvegicus#literature*708348#!ecNumber*3.4.21.109#molecularWeight*33000#molecularWeightMaximum*#commentary*SDS-PAGE, reducing condition, protease inhibitor cocktail, Western blotting using an anti-myc antibody in a sample of medium, two bands 93 kDa and 33 kDa are visible, 33 kDa fragment is a cleavage product of the carboxyl-terminal part#organism*Rattus norvegicus#literature*707577#!ecNumber*3.4.21.109#molecularWeight*33000#molecularWeightMaximum*#commentary*SDS-PAGE and Western blot, reducing conditions, proteolytically active, disulfide two-chain matriptase C-terminal fragment found in both the apical and basolateral media of stably transfected Madin-Darby canine kidney cells#organism*Rattus norvegicus#literature*707786#!ecNumber*3.4.21.109#molecularWeight*35000#molecularWeightMaximum*#commentary*catalytic domain, Asp603 - Val855, before treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis#organism*Rattus norvegicus#literature*696852#!ecNumber*3.4.21.109#molecularWeight*40000#molecularWeightMaximum*#commentary*catalytic domain, Asp603 - Val855, before treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis#organism*Rattus norvegicus#literature*696852#!ecNumber*3.4.21.109#molecularWeight*43000#molecularWeightMaximum*#commentary*under non-reducing conditions in a sample of medium three bands 61 kDa, 55 kDa, 43 kDa are visible using Western blotting with a anti-myc antibody#organism*Rattus norvegicus#literature*707577#!ecNumber*3.4.21.109#molecularWeight*45000#molecularWeightMaximum*#commentary*noncatalytic domain, identified by SDS-PAGE, Western blot analysis and LC-MS,MS#organism*Homo sapiens#literature*695463#!ecNumber*3.4.21.109#molecularWeight*55000#molecularWeightMaximum*#commentary*under non-reducing conditions in a sample of medium three bands 61 kDa, 55 kDa, 43 kDa are visible using Western blotting with a anti-myc antibody#organism*Rattus norvegicus#literature*707577#!ecNumber*3.4.21.109#molecularWeight*60000#molecularWeightMaximum*#commentary*serine protease domain, dimer, determined by SDS-PAGE and Western blot analysis#organism*Homo sapiens#literature*697182#!ecNumber*3.4.21.109#molecularWeight*61000#molecularWeightMaximum*#commentary*under non-reducing conditions in a sample of medium three bands 61 kDa, 55 kDa, 43 kDa are visible using Western blotting with a anti-myc antibody#organism*Rattus norvegicus#literature*707577#!ecNumber*3.4.21.109#molecularWeight*70000#molecularWeightMaximum*#commentary*1 * 70000 + 1 * 240000, complex purified from milk, SDS-PAGE#organism*Homo sapiens#literature*651092#!ecNumber*3.4.21.109#molecularWeight*70000#molecularWeightMaximum*#commentary*SDS-PAGE#organism*Homo sapiens#literature*652059#!ecNumber*3.4.21.109#molecularWeight*70000#molecularWeightMaximum*#commentary*non-complexed form, SDS-PAGE#organism*Homo sapiens#literature*652223#!ecNumber*3.4.21.109#molecularWeight*70000#molecularWeightMaximum*#commentary*immunoblotting, latent NH2 terminal processed form matripase#organism*Homo sapiens#literature*671215#!ecNumber*3.4.21.109#molecularWeight*70000#molecularWeightMaximum*#commentary*x * 70000, inactive zymogen, SDS-PAGE#organism*Homo sapiens#literature*683047#!ecNumber*3.4.21.109#molecularWeight*70000#molecularWeightMaximum*#commentary*SDS-PAGE, reducing condition, and Western blot, latent form of matriptase#organism*Homo sapiens#literature*709136#!ecNumber*3.4.21.109#molecularWeight*70000#molecularWeightMaximum*#commentary*x * 70000, SDS-PAGE#organism*Homo sapiens#literature*717799#!ecNumber*3.4.21.109#molecularWeight*70000#molecularWeightMaximum*#commentary*x * 70000, SDS-PAGE; x * 70000, SDS-PAGE#organism*Homo sapiens#literature*717902#!ecNumber*3.4.21.109#molecularWeight*70000#molecularWeightMaximum*#commentary*x * 70000, matriptase zymogen, SDS-PAGE, x * 30000, matriptase serine protease domain, SDS-PAGE#organism*Homo sapiens#literature*732088#!ecNumber*3.4.21.109#molecularWeight*75000#molecularWeightMaximum*#commentary*calculated from nucleic acid sequence#organism*Homo sapiens#literature*651926#!ecNumber*3.4.21.109#molecularWeight*75000#molecularWeightMaximum*#commentary*gelatin zymography, soluble active enzyme#organism*Homo sapiens#literature*673572#!ecNumber*3.4.21.109#molecularWeight*75000#molecularWeightMaximum*#commentary*by immunoblotting or zymography#organism*Homo sapiens#literature*675024#!ecNumber*3.4.21.109#molecularWeight*75000#molecularWeightMaximum*#commentary*x * 75000, native enzyme, SDS-PAGE#organism*Homo sapiens#literature*683332#!ecNumber*3.4.21.109#molecularWeight*80000#molecularWeightMaximum*#commentary*noncomplexed form purified from T47D cells, SDS-PAGE#organism*Homo sapiens#literature*651092#!ecNumber*3.4.21.109#molecularWeight*80000#molecularWeightMaximum*#commentary*SDS-PAGE, recombinant protease domain#organism*Homo sapiens#literature*652029#!ecNumber*3.4.21.109#molecularWeight*80000#molecularWeightMaximum*#commentary*immunoblotting, membrane-bound enzyme#organism*Homo sapiens#literature*673572#!ecNumber*3.4.21.109#molecularWeight*80000#molecularWeightMaximum*#commentary*x * 95000, full-length transmembrane isoform, SDS-PAGE, x * 80000, Gly149-early processed isoform, SDS-PAGE, x * 26000-29000, activated recombinant truncated wild-type catalytic domain, SDS-PAGE#organism*Homo sapiens#literature*683674#!ecNumber*3.4.21.109#molecularWeight*80000#molecularWeightMaximum*#commentary*serine protease domain, identified by SDS-PAGE, Western blot analysis and LC-MS,MS, including serpin complex#organism*Homo sapiens#literature*695463#!ecNumber*3.4.21.109#molecularWeight*84000#molecularWeightMaximum*#commentary*calculated molecular mass#organism*Homo sapiens#literature*697904#!ecNumber*3.4.21.109#molecularWeight*85000#molecularWeightMaximum*#commentary*and 95000 Da, SDS-PAGE, complex derived from milk#organism*Homo sapiens#literature*651927#!ecNumber*3.4.21.109#molecularWeight*85000#molecularWeightMaximum*#commentary*SDS-PAGE, full length enzyme#organism*Homo sapiens#literature*652029#!ecNumber*3.4.21.109#molecularWeight*85000#molecularWeightMaximum*#commentary*immunoblotting, full-length hepatocyte growth factor activator inhibitor-1 complexed with the serine protease domain of matripase#organism*Homo sapiens#literature*671215#!ecNumber*3.4.21.109#molecularWeight*85000#molecularWeightMaximum*#commentary*Western blot analysis using seminal fluid, seminal fluid contains only activated matriptase in complex with hepatocyte growth factor activator inhibitor-1 (HAI-1), supposed 70 kDa active matriptase and a 15 kDa HAI-fragment#organism*Homo sapiens#literature*707054#!ecNumber*3.4.21.109#molecularWeight*85000#molecularWeightMaximum*#commentary*SDS-PAGE and Western blot, reducing conditions, cleaved form of the enzyme#organism*Homo sapiens#literature*709407#!ecNumber*3.4.21.109#molecularWeight*88900#molecularWeightMaximum*#commentary*#organism*Homo sapiens#literature*699127#!ecNumber*3.4.21.109#molecularWeight*90000#molecularWeightMaximum*#commentary*x * 90000, SDS-PAGE#organism*Mus musculus#literature*657796#!ecNumber*3.4.21.109#molecularWeight*90000#molecularWeightMaximum*#commentary*Western blot analysis, post-translational processed enzyme, cleavage between Gly149 and Ser150 within the SEA domain#organism*Rattus norvegicus#literature*671832#!ecNumber*3.4.21.109#molecularWeight*90000#molecularWeightMaximum*#commentary*Western blot analysis using conditioned medium, proteolytically inactive single-chain C-terminal fragment#organism*Rattus norvegicus#literature*707795#!ecNumber*3.4.21.109#molecularWeight*90000#molecularWeightMaximum*#commentary*SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, non-activated C-terminal part; SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, non-activated form of matriptase#organism*Rattus norvegicus#literature*708273#!ecNumber*3.4.21.109#molecularWeight*90000#molecularWeightMaximum*#commentary*SDS-PAGE and Western blot analysis, reducing conditions, non-activated enzyme, single-chain C-terminal fragment#organism*Rattus norvegicus#literature*708947#!ecNumber*3.4.21.109#molecularWeight*93000#molecularWeightMaximum*#commentary*immunoblotting, latent full-length matripase#organism*Homo sapiens#literature*671215#!ecNumber*3.4.21.109#molecularWeight*93000#molecularWeightMaximum*#commentary*SDS-PAGE, reducing condition, protease inhibitor cocktail, Western blotting using an anti-myc antibody in a sample of medium, two bands 93 kDa and 33 kDa are visible. 93 kDa fragment represents released single-chain carboxyl-terminal part#organism*Rattus norvegicus#literature*707577#!ecNumber*3.4.21.109#molecularWeight*93000#molecularWeightMaximum*#commentary*SDS-PAGE and Western blot, reducing conditions, proteolytically inactive, single-chain matriptase C-terminal fragment found in both the apical and basolateral media of stably transfected Madin-Darby canine kidney cells#organism*Rattus norvegicus#literature*707786#!ecNumber*3.4.21.109#molecularWeight*95000#molecularWeightMaximum*#commentary*complexed with HAI-1, purified from milk, SDS-PAGE#organism*Homo sapiens#literature*651092#!ecNumber*3.4.21.109#molecularWeight*95000#molecularWeightMaximum*#commentary*complex can be converted by boiling to matriptase plus a 40000 Da protein doublet#organism*Homo sapiens#literature*651926#!ecNumber*3.4.21.109#molecularWeight*95000#molecularWeightMaximum*#commentary*and 85000 Da, SDS-PAGE, complex derived from milk#organism*Homo sapiens#literature*651927#!ecNumber*3.4.21.109#molecularWeight*95000#molecularWeightMaximum*#commentary*gelatin zymography or immunoblotting, matripase/hepatocyte growth factor activator inhibitor complex#organism*Homo sapiens#literature*673572#!ecNumber*3.4.21.109#molecularWeight*95000#molecularWeightMaximum*#commentary*x * 95000, single-chain latent enzyme, SDS-PAGE, x * 120000, active enzyme in complex with inhibitor HAI-1, SDS-PAGE#organism*Homo sapiens#literature*683494#!ecNumber*3.4.21.109#molecularWeight*95000#molecularWeightMaximum*#commentary*x * 95000, full-length transmembrane isoform, SDS-PAGE, x * 80000, Gly149-early processed isoform, SDS-PAGE, x * 26000-29000, activated recombinant truncated wild-type catalytic domain, SDS-PAGE#organism*Homo sapiens#literature*683674#!ecNumber*3.4.21.109#molecularWeight*95000#molecularWeightMaximum*#commentary*extracellular domains, Tyr81 - Val855, before treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis#organism*Rattus norvegicus#literature*696852#!ecNumber*3.4.21.109#molecularWeight*95000#molecularWeightMaximum*#commentary*Western blot analysis using seminal fluid or urine, seminal fluid or urine contain only activated matriptase in complex with hepatocyte growth factor activator inhibitor-1 (HAI-1), supposed 70 kDa active matriptase and a 25 kDa HAI-fragment#organism*Homo sapiens#literature*707054#!ecNumber*3.4.21.109#molecularWeight*95000#molecularWeightMaximum*#commentary*Western blot analysis, reducing conditions#organism*Homo sapiens#literature*708768#!ecNumber*3.4.21.109#molecularWeight*100000#molecularWeightMaximum*#commentary*immunoblotting, matripase-hepatocyte growth factor activator inhibitor-1 complex#organism*Homo sapiens#literature*674410#!ecNumber*3.4.21.109#molecularWeight*110000#molecularWeightMaximum*#commentary*Western blot analysis, unprocessed enzyme#organism*Rattus norvegicus#literature*671832#!ecNumber*3.4.21.109#molecularWeight*110000#molecularWeightMaximum*#commentary*gelatin zymography or immunoblotting, matripase/hepatocyte growth factor activator inhibitor complex#organism*Homo sapiens#literature*673572#!ecNumber*3.4.21.109#molecularWeight*110000#molecularWeightMaximum*#commentary*matripase complex#organism*Homo sapiens#literature*695463#!ecNumber*3.4.21.109#molecularWeight*120000#molecularWeightMaximum*#commentary*complexed form, SDS-PAGE#organism*Homo sapiens#literature*652223#!ecNumber*3.4.21.109#molecularWeight*120000#molecularWeightMaximum*#commentary*immunoblotting, 70000 active matripase plus full-length hepatocyte growth factor activator inhibitor-1#organism*Homo sapiens#literature*671215#!ecNumber*3.4.21.109#molecularWeight*120000#molecularWeightMaximum*#commentary*x * 95000, single-chain latent enzyme, SDS-PAGE, x * 120000, active enzyme in complex with inhibitor HAI-1, SDS-PAGE#organism*Homo sapiens#literature*683494#!ecNumber*3.4.21.109#molecularWeight*120000#molecularWeightMaximum*#commentary*SDS-PAGE, reducing condition, and Western blot, activated form of matriptase in complex with hepatocyte growth factor activator inhibitor 1#organism*Homo sapiens#literature*709136#!ecNumber*3.4.21.109#molecularWeight*130000#molecularWeightMaximum*#commentary*SDS-PAGE and Western blot, reducing conditions, matriptase-hepatcyte growth factor activator inhibitor-1 complex#organism*Homo sapiens#literature*709407#!ecNumber*3.4.21.109#molecularWeight*240000#molecularWeightMaximum*#commentary*1 * 70000 + 1 * 240000, complex purified from milk, SDS-PAGE#organism*Homo sapiens#literature*651092#